A Clinical Study Of Danhong Injection In The Treatment Of Old Patients With Ischemic Cardiocerebrovascular Diseases

BackgroundIt is known that the major adverse cardiovascular events (MACE) are related closely with the rupture of atherosclerotic plaque and its secondary thrombosis. Platelet aggregation is the key onset factor in the process of thrombosis. There had ever been trials in animals showed that Danhong Injection could inhibit platelet aggregation and prevent from artery thrombosis. However, It is still unclear how about the clinical treatment effects and the safety were in the elderly patients.ObjectiveTo investigate the clinical effects and safety of Danhong Injection (DHI) in treating elderly patient of with ischemic cardiocerebrovascular diseases, also detect the possible mechanisms.Methods(1)155 patients with coronary heart disease (CHD) were divided into three groups according to its subtypes:AMI group, UAP group and SAP group. Serum levels of high-sensitivity C-reaction protein (hsCRP),homocysteinemia (Hcy) and circulatory endothelial cells (Cecil) were measured respectively in the beginning and the end of the study. (2) 210 old patients aged over 60 with ischemic cardiocerebrovascular diseases were randomized to the treatment group (150 cases) and the control group (60 cases). All patients were administered with routine medication. Upon routine treatment, DHI 40ml+5%GS 250ml was administered intravenously to the patients in the treatment group, Prostaglandin E1 10μg was given intravenously to the patients in the control group. Analysis was made by SPSS 13.0 and P<0.01 was significant. Results(1) The periphery serum numbers of CEC in AMI and UAP group were increased significantly than SAP group. However, the difference of periphery serum CEC numbers between AMI group and UAP group was not significant. The periphery serum levels of Hcy in AMI group were higher significantly than that in UAP and SAP group but the difference between the UAP and SAP group was not significant. Serum levels of hsCRP in AMI group were higher significantly than that in UAP and SAP groups. Other than that, it was also higher of Serum levels of hsCRP in UAP group than that in SAP group and the difference was statistically significant. (2)There was a significant difference in the inhibition rate of the ADP and AA induced platelet aggregation in each group after treatment. The difference of the ADP induced platelet aggregation rate was statistically significant between the two groups (p<0.01) but that was not concerning for AA induced platelet aggregation rate. The plasma levels of fibrinogen and D-dimer in the treatment group were significantlly decreased after threatment (p<0.05, p<0.01) compared with the control group. The plasma levels of hsCRP and Hcy in the treatment group were also significantly decreased after theatment (p<0.05) compared with the control group. The post-treatment plasma CECs were all decreased compared with pre-treatment in each groups (p<0.01), but the difference between the two groups was not statistically significant.Conclusion1. The numbers of periphery CECs, the levels of hsCRP and Hcy all increased following worsening of CHD and could be a indicator to evaluating the severity of CHD.2. Serum levels of hsCRP in AMI group were higher significantly than that in UAP and SAP groups and it was also higher in UAP group than that in SAP group. It suggested that it was related closely with the progression of atherosclerosis and the stability of the atherosclerotic plaqe. It could be a predicting factor for MACE. 3. Danhong injection could decrease serum Hey levels significantly and it suggested that Danhong injection could retard the progression of the atherosclerosis.4. Danhong injection could decrease periphery CECs, inhibit platelet aggreagation significantly from both AA and ADP routes, decrease serum hsCRP and fibrinogen levels significantly. It suggested that Danhong injection could protect the endothelial cells from injury, decrease artery inflammation, reduce the risk of artery thrombosis.5. Danhong injection is effective and safe in treating the old patients suffered from ischemic cardiocerebrovascular diseases.